TAO Synergies Inc (TAOX) is a company operating across cryptocurrency asset holdings and pharmaceutical drug development, as described in its 10-K filed March 31, 2026 (accession 000110465926037915). The filing indicates the company holds TAO crypto assets and participates in blockchain network activities such as staking, while also pursuing drug development subject to FDA review and healthcare regulatory oversight. The company has disclosed it requires additional financing to continue operations, with capital raised through public or private offerings of common or preferred stock and other equity-linked securities. TAO Synergies is not yet generating self-sustaining revenue, operating under conditions of illiquidity and insufficient cash flows as explicitly cited in its own risk disclosures. The 10-K covers the fiscal year ended on a date not fully legible in the provided excerpts. Leadership, founding year, headquarters, and exchange listing details were not determinable from the available filing excerpts.

Revenue model

The filing does not disclose specific revenue streams, amounts, or a defined pricing model. The company references crypto asset holdings and staking activities as operational activities, and drug development as a separate business line, but no revenue figures or revenue model details are supported by the provided excerpts.

Products and services

TAO crypto asset holdings and blockchain network participation, including staking. Pharmaceutical drug development subject to FDA marketing application and review processes. Specific drug candidates or product names are not identified in the available filing excerpts.

Customers and end markets

The filing references Medicare, Medicaid, and federal healthcare programs in the context of regulatory compliance, suggesting healthcare payers as a potential end market for pharmaceutical activities. No specific customers, customer counts, or end market revenue breakdowns are disclosed in the available excerpts.

Value-chain role

The company appears to operate as a crypto asset holder and blockchain network participant on one side, and as an early-stage drug developer subject to FDA approval processes on the other. Its precise position in either value chain is not fully defined in the available excerpts.

Geographic exposure

The filing references regulatory exposure in the United States and the European Economic Area, including GDPR compliance obligations and data localization requirements in unspecified foreign countries. No revenue geographic breakdown is disclosed.

Source: SEC 10-K, filed 2026-03-31

Industry: Finance Services Peers: Applied Therapeutics, Inc. Dyadic International Inc Cidara Therapeutics, Inc. Quince Therapeutics Inc Galera Therapeutics Inc Scorpius Holdings, Inc. Lantern Pharma Inc Minerva Neurosciences Inc Mustang Bio Inc